Journal article
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
Abstract
BACKGROUND: Chronic rhinosinusitis with nasal polyps affects approximately 2-4% of the general population, and long-term use of systemic corticosteroids is associated with adverse effects. The aim of this study was to assess the efficacy and safety of mepolizumab in adults with recurrent, refractory severe bilateral chronic rhinosinusitis with nasal polyps.
METHODS: SYNAPSE was a randomised, double-blind, placebo-controlled, parallel-group, …
Authors
Han JK; Bachert C; Fokkens W; Desrosiers M; Wagenmann M; Lee SE; Smith SG; Martin N; Mayer B; Yancey SW
Journal
The Lancet Respiratory Medicine, Vol. 9, No. 10, pp. 1141–1153
Publisher
Elsevier
Publication Date
October 2021
DOI
10.1016/s2213-2600(21)00097-7
ISSN
2213-2600